These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 31968115)

  • 1. Association of Potentially Modifiable Diabetes Care Factors With Glycemic Control in Patients With Insulin-Treated Type 2 Diabetes.
    Lauffenburger JC; Lewey J; Jan S; Lee J; Ghazinouri R; Choudhry NK
    JAMA Netw Open; 2020 Jan; 3(1):e1919645. PubMed ID: 31968115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of Targeted Insulin-Adherence Interventions for Glycemic Control Using Predictive Analytics Among Patients With Type 2 Diabetes: A Randomized Clinical Trial.
    Lauffenburger JC; Lewey J; Jan S; Makanji S; Ferro CA; Krumme AA; Lee J; Ghazinouri R; Haff N; Choudhry NK
    JAMA Netw Open; 2019 Mar; 2(3):e190657. PubMed ID: 30874782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin: A Randomized Clinical Trial.
    Martens T; Beck RW; Bailey R; Ruedy KJ; Calhoun P; Peters AL; Pop-Busui R; Philis-Tsimikas A; Bao S; Umpierrez G; Davis G; Kruger D; Bhargava A; Young L; McGill JB; Aleppo G; Nguyen QT; Orozco I; Biggs W; Lucas KJ; Polonsky WH; Buse JB; Price D; Bergenstal RM;
    JAMA; 2021 Jun; 325(22):2262-2272. PubMed ID: 34077499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
    Dahl D; Onishi Y; Norwood P; Huh R; Bray R; Patel H; Rodríguez Á
    JAMA; 2022 Feb; 327(6):534-545. PubMed ID: 35133415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk Factors for Nocturnal Hypoglycemia in Insulin-treated Patients With Type 2 Diabetes: A Secondary Analysis of Observational Data Derived From an Integrated Clinical Trial Database.
    Bae JP; Duan R; Fu H; Hoogwerf BJ
    Clin Ther; 2017 Sep; 39(9):1790-1798.e7. PubMed ID: 28781218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization.
    Hayward RA; Manning WG; Kaplan SH; Wagner EH; Greenfield S
    JAMA; 1997 Nov; 278(20):1663-9. PubMed ID: 9388085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Cumulative Multimorbidity, Glycemic Control, and Medication Use With Hypoglycemia-Related Emergency Department Visits and Hospitalizations Among Adults With Diabetes.
    McCoy RG; Lipska KJ; Van Houten HK; Shah ND
    JAMA Netw Open; 2020 Jan; 3(1):e1919099. PubMed ID: 31922562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of adherence and weight loss on glycemic control in patients with type 2 diabetes: cohort analyses of integrated medical record, pharmacy claims, and patient-reported data.
    McAdam-Marx C; Bellows BK; Unni S; Wygant G; Mukherjee J; Ye X; Brixner DI
    J Manag Care Spec Pharm; 2014 Jul; 20(7):691-700. PubMed ID: 24967522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementation of a Health Plan Program for Switching From Analogue to Human Insulin and Glycemic Control Among Medicare Beneficiaries With Type 2 Diabetes.
    Luo J; Khan NF; Manetti T; Rose J; Kaloghlian A; Gadhe B; Jain SH; Gagne JJ; Kesselheim AS
    JAMA; 2019 Jan; 321(4):374-384. PubMed ID: 30694321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Real-time Continuous Glucose Monitoring With Glycemic Control and Acute Metabolic Events Among Patients With Insulin-Treated Diabetes.
    Karter AJ; Parker MM; Moffet HH; Gilliam LK; Dlott R
    JAMA; 2021 Jun; 325(22):2273-2284. PubMed ID: 34077502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Voice-Based Conversational Artificial Intelligence for Basal Insulin Prescription Management Among Patients With Type 2 Diabetes: A Randomized Clinical Trial.
    Nayak A; Vakili S; Nayak K; Nikolov M; Chiu M; Sosseinheimer P; Talamantes S; Testa S; Palanisamy S; Giri V; Schulman K
    JAMA Netw Open; 2023 Dec; 6(12):e2340232. PubMed ID: 38039007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA1c on glycemic control in patients with type 2 diabetes: the Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial.
    Kennedy L; Herman WH; Strange P; Harris A;
    Diabetes Care; 2006 Jan; 29(1):1-8. PubMed ID: 16373887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of an mHealth-enabled hierarchical diabetes management intervention in primary care in China (ROADMAP): A cluster randomized trial.
    Jia W; Zhang P; Zhu D; Duolikun N; Li H; Bao Y; Li X;
    PLoS Med; 2021 Sep; 18(9):e1003754. PubMed ID: 34547030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis.
    McAdam-Marx C; Nguyen H; Schauerhamer MB; Singhal M; Unni S; Ye X; Cobden D
    Clin Ther; 2016 Dec; 38(12):2642-2651. PubMed ID: 27889301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycemic relapse in type 2 diabetes.
    Graber AL; Shintani AK; Wolff K; Brown A; Elasy TA
    Endocr Pract; 2006; 12(2):145-51. PubMed ID: 16690461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy.
    Lapolla A; Frison V; Bettio M; Dal Pos M; Rocchini P; Panebianco G; Tadiotto F; Da Tos V; D'Ambrosio M; Marangoni A; Ferrari M; Pianta A; Balzano S; Confortin L; Lamonica M; Marin N; Strazzabosco M; Brun E; Mesturino CA; Simoncini M; Zen F; Bax G; Bonsembiante B; Cardone C; Dal Frà MG; Gallo A; Masin M; Piarulli F; Sartore G; Simioni N
    Clin Ther; 2015 Mar; 37(3):574-84. PubMed ID: 25626486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond HbA1c.
    Bloomgarden Z
    J Diabetes; 2017 Dec; 9(12):1052-1053. PubMed ID: 28792665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "Act on Threes" Paradigm for Treatment Intensification of Type 2 Diabetes in Managed Care: Results of a Randomized Controlled Study with an Educational Intervention Targeting Improved Glycemic Control.
    Bieszk N; Reynolds SL; Wei W; Davis C; Kamble P; Uribe C
    J Manag Care Spec Pharm; 2016 Sep; 22(9):1028-38. PubMed ID: 27579824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are patients on basal insulin attaining glycemic targets? Characteristics and goal achievement of patients with type 2 diabetes mellitus treated with basal insulin and physician-perceived barriers to achieving glycemic targets.
    Dalal MR; Grabner M; Bonine N; Stephenson JJ; DiGenio A; Bieszk N
    Diabetes Res Clin Pract; 2016 Nov; 121():17-26. PubMed ID: 27616634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial.
    Libman IM; Miller KM; DiMeglio LA; Bethin KE; Katz ML; Shah A; Simmons JH; Haller MJ; Raman S; Tamborlane WV; Coffey JK; Saenz AM; Beck RW; Nadeau KJ;
    JAMA; 2015 Dec; 314(21):2241-50. PubMed ID: 26624824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.